Results 141 to 150 of about 1,011,686 (269)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Breast Cancer: Molecular Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Samad MA, Ahmad I, Khan MR, Suhail M, Zughaibi TA, Al-Abbasi FA, Alhosaini KA, Khan MS, Kumer A, Tabrez S.   +9 more
europepmc   +1 more source

Thinking Well: A randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs

, 2015
Helen Waller, Richard Emsley, Daniel Freeman, Paul Bebbington, Graham Dunn, David Fowler, Amy Hardy, Elizabeth Kuipers, Philippa Garety   +8 more
openalex   +1 more source

Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies [PDF]

, 2016
Mohammad Jafri, Shakeel Ahmed Ansari, Mohammed Al‐Qahtani, Jerry W. Shay   +3 more
openalex   +1 more source

Targeting ferroptosis-based cancer therapy using nanomaterials: strategies and applications

, 2021
Lianxiang Luo, Han Wang, Wen Tian, Xiaoling Li, Zheng Zhu, Riming Huang, Hui Luo   +6 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Zhou XJ.
europepmc   +1 more source

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers

, 2016
Simon Thomas, Karin Straathof, Nourredine Himoudi, John Anderson, Martin Pulè   +4 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Extracellular vesicles in metabolic perspective: mechanism and targeted therapy. [PDF]

J Nanobiotechnology
Sheng Q, Wu Z, Li W, Wang L, Xu H, Wang W, Yan Z, Ge G, Xu Y, Geng D.   +9 more
europepmc   +1 more source